AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Two (2) younger Newbies both need better QBs… AND we have another hydrocele
Topics Discussed
Agent Orange Newbie doing well on RT and doublet; younger Newbie with possible variant PrCa needs solid GU med onc; 2nd younger Newbie also needs to upgrade his MO – is he stuck in doublet?; scans suggest Jevtana not holding disease – pasritamig trial next?; debulking to start with IMRT; does coffee creamer interfere with treatment?; hydrocele not the first time for AnCan; nocturia and RT proctitis cause problems; Orgovyx coming soon; Dr. E in his future
John, thank you for the recommendation! And yes, I can get to UofC easily! I just retired…..lots of free time!
Don Rogers sent: 4:08 PM
Hi John, Nice to hear you are doing well. Everything here in Boca Raton is also wonderful. I am doing great, PSA still undetectible. Looking forward to going on a Disney Cruise with the entire family in early July. Mary and I then go on a 10 day camping trip to Yellowstone. Let me what you find out at your 3 month visit with your oncologist. My best always, Don
Len Sierra sent: 4:21 PM
EZH2 inhibitors: Mevrometostat (PF-06821497): An investigational selective inhibitor of enhancer of zeste homolog 2 (EZH2) being studied in combination with XTANDI for mCRPC. Several Phase 3 trials (MEVPRO-1 and MEVPRO-2) are ongoing.
Bob McHugh sent: 4:49 PM
Lomotil or Immodium?
Jim Ekrut, Ft. Worth, TX sent: 4:51 PM
Imodium doesn’t seem to help much. I’m hoping the gastroenterologist will prescribe Lomotil, but he initially hesitated because it’s a controlled substance.
Jim Marshall, Vet Sup Grp. Moderator sent: 4:56 PM
The LATITUDE Trial, 2017, had HS Abi + 10mg. and a few years later HS dropped to 5mg although CR stayed at 10mg. Jim M
Jim Ekrut, Ft. Worth, TX sent: 5:04 PM
Thanks so much for a helpful session! Until next time.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer.
——————————————————————————————————–
2nd Thursday of each month at 8 pm Eastern in The Barniskis Room (222-583-973)
Predicting Radiation Side Effects – PROSTOX Webinar with interesting updates!
Last year, we presented a webinar on predicting Prostate Cancer Radiation Treatment side effects with PROSTOX before treatment begins. By analyzing your unique genetics, you can make smarter, more informed decisions to avoid side effects and safeguard your quality of life for years to come.
PROSTOX Standard (previously PROSTOX CFRT+) predicts late grade ≥2 toxicity from conventionally fractionated (CFRT) or moderately hypofractionated (MHFRT) radiation therapy for patients with localized prostate cancer. Together with PROSTOX Ultra, which is already available for patients considering stereotactic body radiation therapy (SBRT), the PROSTOX portfolio now provides risk assessment across a broader range of external beam radiation therapy (EBRT) types. We’ll discuss the updates and other patient concerns, such as insurance coverage and questions to bring to your doctors.
PCPEP – The Prostate Cancer Patient Empowerment Program: Improve Your Quality of Life
PCPEP – learn how to employ the Science and Practice of an Anti‑Inflammatory Lifestyle – With Dr. Rob Rutledge
AnCan is all about survivorship – improving Quality of Life after diagnosis, with a focus on diet/nutrition, exercise, stress management, and more.
We now welcome PCPEP (Prostate Cancer Patient Empowerment Program), a Canadian-based program at Dalhousie University in Halifax, Nova Scotia. https://pcpep.org to our AnCan family.
PCPEP’s goal is to optimize survivorship for prostate cancer patients and others. It does this through daily emails and videos focused on components that contribute to your QoL – exercise, nutrition, stress reduction, and the social connection that makes AnCan a big family.
Watch Co-founder Dr. Rob Rutledge, a GU radiation oncologist, explain the program.
The program is FREE and currently open to ALL men with a prostate cancer diagnosis. Although the presentation was made to Gents in early Active Surveillance, it is open to all levels.
AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Two men recur from low levels, one younger, while a much younger man is denovo metastatic.
Topics Discussed
Fit 87 yr old seeks more treatment ideas; younger man recurs post-LDR brachy for 3+4; – cud be a NCI candidate; 3+3 comes back after 5 yrs as 4+5; PSA stays high but stable after 9 months of doublet – change docs!; Clomid causing heart issues; Long Game candidate gives update; Axumin goes AWOL; another very young Newbie with multiple 5+5 cores needs a GU MO; Gent switches care at MSKCC
Good luck John B. I must ring off for tonight, best wishes to one and all! — Alfredo
Morgan Brooke sent: 4:36 PM
Okay. I thought I was here in the first 10 minutes. I’ll be sure to join earlier next week. Thank you
Jim Marshall, Vet Support Grp. Moderator sent: 4:36 PM
Jack. – welcome to the CLUB!!!!!
Jeff Marchi – San Francisco sent: 4:38 PM
morgan too many new people today
Morgan Brooke sent: 4:38 PM
Understood
Jeff Marchi – San Francisco sent: 4:40 PM
get here 10 minutes before the meeting
Danny sent: 4:50 PM
you looking for folks to speak?
Danny sent: 4:53 PM
Jun 2022 PSA=4 (no actions taken) Nov 2025 PSA=13 Nov 2025 MRI PiRADs=5 Nov 2025 Biopsy Gleason 10 (5+5) Nov 2025 PSMA PET Local pelvic mets Nov 2025 No Genetic germline or somatic adaptations to treat Dec 2025 Started ADT (Nubeqa 1200mg + Orgovyx 120mg) daily Jan 2026 Blood Panel (PSA=0.45 T=11)
Urology: R. Jeffrey Karnes, MD Onc: Elisabeth Heath, MD RadOnc: Anne Rajkumar, MD
